Document Detail

A longitudinal assessment of thyroid hormone concentrations in preterm infants younger than 30 weeks' gestation during the first 2 weeks of life and their relationship to outcome.
MedLine Citation:
PMID:  11826199     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: This trial examined the effects of triiodothyronine (T3) and hydrocortisone on lung disease. We present here the placebo data as this provides a natural history of thyroid hormone changes in this group of very preterm infants. We also examined the relationship between thyroid hormone levels and the outcome death and ventilator dependence at 2 weeks. METHODS: Plasma-free T3 (FT3), free thyroxine (FT4), total T3, total T4, and thyroid-stimulating hormone were measured prospectively in preterm infants who were <30 weeks' gestation during the first 14 days of life. The data were obtained from the placebo arm of a multicenter, randomized, double-blind, clinical trial of T3 and hydrocortisone, called the THORN Trial. RESULTS: A total of 128 infants were recruited into the placebo group. The mean FT3 level at <5 hours of age was 4.9 pmol/L and remained below this level. FT4 levels decreased from 15 pmol/L to 9.7 pmol/L at 7 days and then increased to 11.0 pmol/L by day 14. Total T3 and total T4 levels fell after 5 hours of age and reached a minimum on day 3. Thyroid-stimulating hormone levels fell markedly from 9.2 mU/L to 1.8 mU/L at 72 hours and then increased to approximately 4 mU/L. We found that all thyroid hormones but particularly FT3 and FT4 hormones were highly significantly related to outcome. The lower the hormone levels, the worse the outcome (death or ventilator dependence at 2 weeks of age). CONCLUSION: 1) Thyroid hormone levels in preterm infants <30 weeks were much lower than in term infants, 2) the postnatal surge of thyroid hormones normally seen at 24 to 48 hours of age in term infants did not occur in our group of preterm infant, and 3) low FT3 and FT4 levels are associated with higher mortality and severity of lung disease.
Sumita Biswas; June Buffery; Helen Enoch; J Martin Bland; Dafydd Walters; Michael Markiewicz
Related Documents :
10447019 - Hypothyroxinemia in premature infants: is thyroxine treatment necessary?
16188789 - Somatostatin treatment of congenital chylothorax may induce transient hypothyroidism in...
17643079 - Thyroid function and dysfunction in premature infants.
6649409 - The foetal thyroid of the dromedary: its relation to body weight and dimensions and to ...
8381799 - Hypothalamic pituitary adrenal function in the extremely low birth weight infant.
24949929 - Sensorineural hearing loss in very low birth weight infants with histological chorioamn...
2531789 - Prediction of successful primary closure of congenital abdominal wall defects using int...
20351659 - Aquaporin-4 gene variation and sudden infant death syndrome.
2017729 - An alternative to unattended delivery--a training programme for village midwives in pap...
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Pediatrics     Volume:  109     ISSN:  1098-4275     ISO Abbreviation:  Pediatrics     Publication Date:  2002 Feb 
Date Detail:
Created Date:  2002-02-04     Completed Date:  2002-03-12     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0376422     Medline TA:  Pediatrics     Country:  United States    
Other Details:
Languages:  eng     Pagination:  222-7     Citation Subset:  AIM; IM    
Department of Child Health, Chelsea & Westminster Hospital, London, United Kingdom.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Age Factors
Double-Blind Method
Gestational Age
Hydrocortisone / therapeutic use
Infant, Newborn
Infant, Premature / blood*
Infant, Premature, Diseases / drug therapy,  mortality
Longitudinal Studies
Respiration, Artificial / utilization
Survival Rate
Thyroid Hormones / blood*
Thyrotropin / blood
Thyroxine / blood
Treatment Outcome
Triiodothyronine / blood,  therapeutic use
Reg. No./Substance:
0/Thyroid Hormones; 50-23-7/Hydrocortisone; 6893-02-3/Triiodothyronine; 7488-70-2/Thyroxine; 9002-71-5/Thyrotropin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Decreased morning serum cortisol levels in children with asthma treated with inhaled fluticasone pro...
Next Document:  Use of hymenal measurements in the diagnosis of previous penetration.